News

Juno Therapeutics and privately held biotech Eureka Therapeutics have entered into an immunotherapy development partnership with Memorial Sloan Kettering Cancer Center (MSK) of New York City. The exclusive license agreement is for joint development of a novel fully-human binding domain targeting B-cell maturation antigen (BCMA), and binding…

Elotuzumab in combination with bortezomib and dexamethasone prolongs the progression free survival of patients with relapsed or refractory multiple myeloma (RRMM), according to the study “Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus Bd for relapsed/refractory multiple myeloma,” recently published in Blood. Current choices…

The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients and their doctors access to personal genomic information which can help guide treatments based on genomic alterations. Over the course of the two-year Molecular Profiling Initiative (MPI), the two institutions aim…

In a video posted on Healio’s Hematology-Oncology page, Dr. Ola Landgren, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, speaks about new treatments and ongoing discoveries in the field of multiple myeloma. A lot is taking place, quickly, according to Landgren. “I…

A three-drug combination that includes thalidomide, in place of cyclophosphamide, prior to an autologous stem cell transplant was seen to improve response rates in multiple myeloma patients, according to  the conclusions of a randomized, open-label Phase 3 trial, titled “VTD is superior to VCD prior to intensive therapy in multiple…

The U.S. Food and Drug Administration has designated Darzalex (daratumumab), in combination with standard-of-care regimens, a breakthrough therapy for people with previously treated multiple myeloma (MM), speeding its clinical development and regulatory review for these patients. The FDA designation is reserved for treatments showing early evidence in clinical studies of substantial improvement over…

A randomized Phase 3 clincal trial has concluded that combining bortezomib (Velcade) with pegylated liposomal doxorubicin (PLD) does not show benefit in treating relapsed or refractory multiple myeloma (MM) patients, compared to bortezomib alone. The data was published in Cancer under the title “Final overall survival results…

Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition usually associated with a poor prognosis. Dana-Farber Cancer Institute researchers tested the effects of a new treatment approach using repeated doses of the immunotherapy drug Yervoy (ipilimumab), showing…

A study has uncovered that elevated body mass index (BMI), a measurement of obesity, increases an individual’s risk of developing multiple myeloma and the disease’s risk of progression. The study, “Adipocytes contribute to the growth and progression of multiple myeloma: Unraveling obesity related differences in adipocyte signaling,” was recently published…

Researchers at the University of Birmingham have found that blocking a specific mechanism in the benign condition monoclonal gammophaty of undetermined significance (MGUS) may prevent the development of multiple myeloma. The findings were published in the journal Leukemia in the study “Citrullination of histone H3…